Introduction: Hypothyroidism is frequently associated with growth failure. In long-standing hypothyroidism the growth hormone (GH) secretory responses to growth hormone-releasing hormone (GRH) and insulin-induced hypoglycemia are decreased. Methods: To investigate whether hypothyroidism of short duration affects pituitary GH release, we measured the serum GH response to synthetic GRH (1-29), 1g/ kg body weight, given IV to six athyreotic patients during thyroxine (T4) treatment and one month after stopping T4 (short-term hypothyroid state). This served as a direct measure of pituitary somatotroph function .We also assessed the serum GH response to insulin-induced hypoglycemia in three patients as an indirect assessment of hypothalamic function. Results: We found that basal GH levels remained the same both during (euthyroid state) and after stopping T4 therapy (hypothyroid state). Peak serum GH response to GRH was significantly greater in patients while they were hypothyroid than during T4 therapy when they were euthyroid (p< 0.01). There was no difference in the peak serum GH response to hypoglycemia during and after stopping T4 replacement (30.3 + 8.9 g/L euthyroid-state versus 45 + 14.5 g/L short term hypothyroid-state). Discussion: These results suggest that, in contrast to long standing hypothyroidism, thyroid hormone deficiency of short duration increases somatotroph sensitivity to GRH, perhaps as a result of decreased endogenous hypothalamic IGF-1 release and/or tone.
INTRODUCTION
Thyroid hormones regulate normal utilization of energy and production of heat by the body. In addition to being critical direct biological regulators of normal growth and development, thyroxine (T4) and triiodothyronine (T3), influence and interact with the growth hormone (GH)-insulinlike growth factor-I (IGF-1) axis, as well as with other growth regulating hormones. Hypothyroidism is almost always associated with growth failure.IGF-1, referred to as somatostatin-C in the past, is a growth factor that functions in several metabolic pathways, that is secreted by the liver in response to GH. The pulsatile GH secretion is primarily regulated by the dynamic interaction between forward signals from hypothalamic GH-releasing hormone (GHRH) and ghrelin with feedback signals from IGF-1 and GH at both the level of the hypothalamus and pituitary. [1] [2] [3] [4] [5] Thyroid hormones are also known to significantly affect GH secretion. [6] [7] [8] [9] Hypothyroid patients and rats show low levels of plasma IGF-1, while hyperthyroid patients show high levels of plasma IGF-1. 10, 11 Longstanding hypothyroidism in man and experimental animals results in low GHRH levels 6, 12 and also in low basal GH levels. [13] [14] [15] [16] Additionally, hypothyroidism has been shown to lead to decreased GH secretory responses to insulin-induced hypoglyce-mia. 16, 17 To date, it has been suggested that the impairment of GH secretion is related to the severity, but not the duration of hypothyroidism. 17, 18 This is in contrast to studies in thyroidectomized rats in which changes in pituitary GH content and synthesis, as well as hypothalamic GHRH and SRIF content and synthesis, appeared to be related to the duration of hypothyroidism. 20 The present study was designed to examine the effect of short-term hypothyroidism. This was achieved by assessing GH secretion in athyreotic patients while they were taking thyroid hormone suppressive therapy and one month after withdrawal from thyroid hormone. We used the serum GH response to synthetic GRH (1-29), a GRH fragment which exhibits full biological activity in vivo 21 and in vitro, 22 as direct measure of pituitary somatotroph function and the serum GH response to insulin-induced hypoglycemia as an indirect assessment of hypothalamic function. We hypothesized that thyroid hormone deficiency of short duration would affect GH secretion differently than that observed in long-standing hypothyroidism.
MATERIALS AND METHODS
Six athyreotic patients (1 man and 5 women) from the Agia Marina Hospital Endocrinology Clinic, Athens, Greece, participated in this study. Ages ranged from 30 to 63 years (mean, 45.3 yr) and body weight ranged from 60 to 83 kg. All patients had undergone suppressive therapy with sodium l-thyroxine (T4), 0.2 mg/day, for at least 2 years after having had a total thyroidectomy and radioiodine ablative therapy for thyroid carcinoma. Annual evaluations for 2 to 10 years follow-up with total body radioiodine scans were negative for local recurrence or distant metastases in all patients. Patients were taking no medications other than at the time of initial examination and all appeared clinically euthyroid. All patients had normal physical examinations and normal blood cell counts, serum chemistry profiles, urinalyses and electrocardiograms. There was no significant change in body weight in any of the patients during the interval between the two studies (during T4 therapy and one month after T4 therapy).
The clinical and laboratory characteristics of the 6 patients were studied during their annual evaluation. After giving their informed consent, the patients underwent GRH and insulin-induced hypoglycemia studies on different days on two occasions: first while taking T4 and again 1 month after stopping T4 treatment. After an overnight fast, an indwelling catheter was placed in a forearm vein at least 30 min before injection of GRH-(1-29), 1g/kg body weight, or regular insulin, 0.1U/kg body weight, between 0800 and 0900 h. Blood samples were obtained for GH and glucose at intervals from 15 min before until 120 min after hormone injection. The patients remained in a supine position throughout the hormone dynamic testing.
Serum GH was measured by liquid-phase RIA. 23 Serum TSH was determined by immunoradiometric assay (Corning Medical and Scientific, Medfield, MA). Serum total T4 (TT4) and total triiodothyronine (TT3) were determined by solidphase RIA (Immunochem Corp., Carson, CA). Serum free Figure 1 : GR response to GRH administration during T4 therapy (euthyroid) and one-month after stopping T4 treatment (hypothyroid). While mean basal serum GH concentrations were similar in both groups, the serum GH response to GRH was significantly elevated in patients one month after stopping T4 therapy from 15 to 60 min after GRH administration. The mean peak GH concentration after GRH was significantly greater when the patients were short-term hypothyroid, compared when they were euthyroid (e.g. under T4 therapy).
T4 index (FT4I) and serum free T3 index (FT3I) were calculated using the TT4 and TT3 values, respectively, and the serum T4 resin uptake. Blood glucose was measured at the bedside with an automatic glucose analyzer.
Statistical comparisons were made using one-way analysis of variance (ANOVA) followed by Duncan's multiple range test or paired Student's t-test, when appropriate. Integrated serum GH responses were determined by calculating the area under the response curve and above the baseline level. The data are expressed as mean + SEM.
RESULTS
While taking T4 all patients had low serum TSH concentrations, two patients had elevated TT4 levels and one had a borderline high FT4I, but all patients had normal TT3 and FT3 levels. None of the patients appeared to be clinically hyperthyroid. One month after stopping T4 therapy, serum TSH concentrations had risen to greater than 36mU/L and FTI had fallen to a very low level in every patient, but total and free thyroid hormone levels, which had fallen to very low levels in one patient were still at the lower limits of normal in the others. None of the patients appeared to "be overtly clinically hypothyroid.More specifically, the glucose nadir after regular insulin, 0.1 U/kg iv, was 1. (Table 1) Mean basal serum GH concentrations were similar during and one month after stopping therapy (1.3 g/L). One month after stopping T4 therapy, serum GH concentrations from 15 to 60 min after injection of GRH were significantly greater than during therapy. The mean peak GH concentration after GRH was also greater one month after stopping T4 therapy than during T4 therapy (20 g/L). (Figure 1 ) Some patients noticed transient, mild facial warmth after GRH injection both during and after stopping T4 therapy.
The administration of insulin either during T4 or one month after stopping T4 therapy, resulted in no differences in the onset of hypoglycemia (15 min after insulin injection), serum glucose nadir (1.2 + 0.1 nmol/L) and duration of hypoglycemia (30-45min). The initial rate that serum GH increased was similar in both groups. Both treatment groups reached a peak response between 45 to 60 min after insulin injection. In addition, there was no difference between the mean peak GH levels (30.3 + 5.3 vs 45 + 14.5 g/L) or integrated areas under the GH response curve (AUC) in the patients while under thyroid hormone therapy or one month after stopping therapy. Serum GH levels at 120 min were greater (<0.05) one month after T4 was stopped, compared to during T4 therapy. All patients experienced symptoms of hypoglycemia during both studies.
DISCUSSION
We report that short-term hypothyroid patients demonstrate increased somatotroph responsiveness to GRH, while the GH response to insulin-induced hypoglycemia remained unchanged. These observations differ from those reported in patients with long-standing, clinically severe hypothyroidism whose GH secretory responses to GRH and insulin-induced hypoglycemia were significantly blunted. 24, 25 These differences suggest that the effects of thyroid hormone deficiency on GH secretion are time dependent. This is similar to our previous findings that show that alteration in the hypothalamic-pituitary-adrenal axis function in states of disturbed thyroid function were dependent on the duration of thyroid dysfunction, with generally more pronounced effects as the duration of thyroid dysfunction increased. [26] [27] [28] [29] Some of our patients were receiving greater than replacement dosages of, T4 as indicated by their relatively high TT4 levels and low TSH levels. However, the mean peak serum GH response to GRH during T4 therapy was not significantly different from that reported in normal, non-obese adults. Although several studies have addressed the relationship between thyroid function and GH secretion, the interrelationships between thyroid hormones and GH-IGF axis is not fully understood. More recently, studies have focused on delineating the mechanism of changes in thyroid hormone levels with assessment of GH-mediated increase of peripheral T4 to T3 deiodination. [30] [31] [32] About 3 decades ago, demonstrated that hypothyroid patients had diminished IGF-1 levels. 25 This suggests that either hypothyroid patients have diminished GH secretion or that that hypothyroidism has direct effects upon IGF-1 production. Recently, thyroid hormones have been shown to regulate growth hormone receptor (GHR) expression in vivo. 33 Animal studies have indicated that there is a complete loss of pulsatile GH secretion a >99% reduction in pituitary GH content, a 50% reduction of hypothalamic GRH content, a >90% reduction in spontaneous GH secretion and a >95% impairment of the response to GRH in short-term hypothyroidism, but that pituitary GH content is decreased by only about half this amount and there is no change in GH release in shortterm hypothyroidism. [34] [35] [36] Akin reported that GH-IGF axis was affected in patients with subclinical hypothyroidism and that T4 replacement prevented some of the abnormal axis function. 37 Children with hypothyroidism, show a significant decrease of GH responsiveness to Clonidine stimulation, and a decreased IFG-1 response to GH stimulation. 38 Recent evidence supports that the effects of thyroid hormone on plasma IGF levels is only partially mediated by GH. Rather, it seems that IGF levels in altered thyroid states are mediated by either direct effects of thyroid hormone on IGF, or by other GH-independent pathways. In mature hypothyroid rats, serum IGF-1 levels are only partially corrected by GH, but are normalized by thyroid hormone replacement. 39 Moreover, T4 administration alone to hypophysectomized or thyroidectomized animals is capable of stimulating IGF-1 activity in the absence of GH. 34 A strong positive thyroid hormone-dependent correlation between thyroid hormone concentrations and IGF-1 levels was reported in thyroidectomized rats.
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CONCLUSION
Several mechanisms may play a role in the growth failure observed in hypothyroidism, including abnormalities of GH secretion, IGF-1 synthesis, among others. Our findings of an almost normal GH response in our short-term, mild hypothyroidism patient cohort further support that the effects of hypothyroidism on the GH-IGF-1 system are time-dependent and dose-dependent. She has extensively studied in the neuroendocrine alterations associated with stress, including the hypothalamic-pituitary-adrenal axis and glucocorticoid signaling, in both clinical and basic science research projects. The bulk of her studies are marked by both a multi-level (in-vivo, in-situ and in-vitro), as well as a multi-disciplinary approach aimed at addressing the structure and function of the nervous system. Johnson's scientific record lists over 250 scientific contributions to the international scientific literature where here published original work as amassed over 5,000 citations. She is on the Editorial Board of core anatomical textbooks and atlases, such as Grey's Anatomy for Students, and has written her own textbook on Neuroanatomy. As a result of her experimental studies, she has actively presented in over 180 scientific meetings, with more than 130 invited lectures at meetings and seminars. She serves on several expert panels as Scientific Peer Reviewer, is a member of over 10 Editorial Boards, and a Reviewer in over 35 journals.
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